<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38341321</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2531-1387</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Hematology, transfusion and cell therapy</Title><ISOAbbreviation>Hematol Transfus Cell Ther</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles are a late marker of inflammation, hypercoagulability and COVID-19 severity.</ArticleTitle><Pagination><StartPage>176</StartPage><EndPage>185</EndPage><MedlinePgn>176-185</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.htct.2023.12.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2531-1379(24)00009-9</ELocationID><Abstract><AbstractText>Exacerbated inflammation and coagulation are a hallmark of COVID-19 severity. Extracellular vesicles (EVs) are intercellular transmitters involved in inflammatory conditions, which are capable of triggering prothrombotic mechanisms. Since the release of EVs is potentially associated with COVID-19-induced coagulopathy, the aim of this study was to evaluate changes in inflammation- and hypercoagulability-related EVs during the first month after symptom onset and to determine whether they are associated with disease severity. Blood samples of patients with mild or severe forms of the disease were collected on three occasions: in the second, third and fourth weeks after symptom onset for the quantification by flow cytometry of CD41A (platelet glycoprotein IIb/IIIa), CD162 (PSGL-1), CD31 (PECAM-1) and CD142 cells (tissue factor). Analysis of variance (ANOVA) with repeated measures, Kruskal-Wallis and correlation tests were used. Eighty-five patients were enrolled, 71% of whom had mild disease. Seventeen uninfected individuals served as controls. Compared to controls, both mild and severe COVID-19 were associated with higher EV-CD31<sup>+</sup>, EV-CD41<sup>+</sup> and EV-CD142<sup>+</sup> levels. All EV levels were higher in severe than in mild COVID-19 only after the third week from symptom onset, as opposed to C-reactive protein and D-dimer levels, which were higher in severe than in mild COVID-19 earlier during disease progression. EV levels were also associated with C-reactive protein and D-dimer levels only after the third week of symptoms. In conclusion, EVs expressing CD41A, CD31, TF, and CD162 appear as late markers of COVID-19 severity. This finding may contribute to the understanding of the pathogenesis of acute and possibly long COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Associa&#xe7;&#xe3;o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barion</LastName><ForeName>B&#xe1;rbara Gomes</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Universidade de Sao Paulo (USP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Tania Rubia Flores da</ForeName><Initials>TRFD</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Yeh-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazetto Fonseca</LastName><ForeName>Bruna de Moraes</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Hematology and Hemotherapy Center of the University of Campinas (UNICAMP), Campinas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okazaki</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothschild</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanello</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Vanderson Geraldo</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa&#xe7;a</LastName><ForeName>Paula Ribeiro</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsi</LastName><ForeName>Fernanda A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o (HCFMUSP), Sao Paulo, Brazil; Department of Pathology, School of Medical Sciences, Universidade de Campinas (UNICAMP), Campinas, Brazil. Electronic address: ferorsi@unicamp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Hematol Transfus Cell Ther</MedlineTA><NlmUniqueID>101725732</NlmUniqueID><ISSNLinking>2531-1379</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Extracellular vesicles</Keyword><Keyword MajorTopicYN="N">Hypercoagulability</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>10</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38341321</ArticleId><ArticleId IdType="pmc">PMC11150502</ArticleId><ArticleId IdType="doi">10.1016/j.htct.2023.12.003</ArticleId><ArticleId IdType="pii">S2531-1379(24)00009-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carvalho ACS, Barros LS de A, Ten&#xf3;rio ECPT, Lopes TP, Lopes LP, Cruz da CM. Moduladores de coagula&#xe7;&#xe3;o alterados comprometem os pacientes infectados com COVID-19 / Altered coagulations modulators compromise COVID-19 infected patients. Brazilian J Heal Rev. 2020;3(5):11624&#x2013;11644. doi: 10.34119/bjhrv3n5-021.</Citation><ArticleIdList><ArticleId IdType="doi">10.34119/bjhrv3n5-021</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva ARF, de Oliveira BR, Bastos BS, da R Fraga D, de OL Souto K, Nunes MEF, et al. Coagulopatias associadas &#xe0; infec&#xe7;&#xe3;o por COVID-19: uma revis&#xe3;o de literatura. Rev Eletr&#xf4;nica Acervo Sa&#xfa;de. 2021;13(9):e8589. doi: 10.25248/reas.e8589.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.25248/reas.e8589.2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Loureiro de Andrade Orsi F, Campos Guerra JC. Hipercoagulabilidade, Eventos tromboemb&#xf3;licos E anticoagula&#xe7;&#xe3;o na Covid-19. Rev da Soc Cardiol do Estado S&#xe3;o Paulo. 2020;30(4):462&#x2013;471. doi: 10.29381/0103-8559/20203004462-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.29381/0103-8559/20203004462-71</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson MW, Lima F, Moraes CRP, Ilich A, Huber SC, Barbosa MS, et al. Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Adv. 2022;6(11):3367&#x2013;3377. doi: 10.1182/bloodadvances.2021006620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006620</ArticleId><ArticleId IdType="pmc">PMC8893951</ArticleId><ArticleId IdType="pubmed">35235941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(11):1404&#x2013;1418. doi: 10.1161/CIRCRESAHA.120.317703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317703</ArticleId><ArticleId IdType="pmc">PMC7641188</ArticleId><ArticleId IdType="pubmed">32938299</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C, Bonifay A, Burtey S, Sabatier F, Cauchois R, Abdili E, et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 2021;5(3):628&#x2013;634. doi: 10.1182/bloodadvances.2020003308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003308</ArticleId><ArticleId IdType="pmc">PMC7846479</ArticleId><ArticleId IdType="pubmed">33560376</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamachary B, Cook C, Kumar A, Spikes L, Chalise P, Dhillon NK. Extracellular vesicle&#x2010;mediated endothelial apoptosis and EV&#x2010;associated proteins correlate with COVID&#x2010;19 disease severity. J Extracell Vesicles. 2021;10(9) doi: 10.1002/jev2.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12117</ArticleId><ArticleId IdType="pmc">PMC8254805</ArticleId><ArticleId IdType="pubmed">34262673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Zhang H, Sun S, Wang L, Sun S. Extracellular vesicles and immunogenic stress in cancer. Cell Death Dis [Internet] 2021;12(10):894. doi: 10.1038/s41419-021-04171-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04171-z</ArticleId><ArticleId IdType="pmc">PMC8486873</ArticleId><ArticleId IdType="pubmed">34599143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagida MS, Arakelyan A, Lebedeva AM, Grivel JC, Shpektor AV, Vasilieva EY, et al. Analysis of extracellular vesicles using magnetic nanoparticles in blood of patients with acute coronary syndrome. Biochem. 2016;81(4):382&#x2013;391. doi: 10.1134/S0006297916040088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297916040088</ArticleId><ArticleId IdType="pmc">PMC4966537</ArticleId><ArticleId IdType="pubmed">27293095</ArticleId></ArticleIdList></Reference><Reference><Citation>French SL, Butov KR, Allaeys I, Canas J, Morad G, Davenport P, et al. Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation. Blood Adv. 2020;4(13):3011&#x2013;3023. doi: 10.1182/bloodadvances.2020001758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001758</ArticleId><ArticleId IdType="pmc">PMC7362363</ArticleId><ArticleId IdType="pubmed">32614966</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#x142;omka A, Urban SK, Lukacs-Kornek V, &#x17b;ekanowska E, Kornek M. Large extracellular vesicles: have we found the holy grail of inflammation? Front Immunol. 2018;9 doi: 10.3389/fimmu.2018.02723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02723</ArticleId><ArticleId IdType="pmc">PMC6300519</ArticleId><ArticleId IdType="pubmed">30619239</ArticleId></ArticleIdList></Reference><Reference><Citation>Voukalis C, Shantsila E, Lip GYH. Microparticles and cardiovascular diseases. Ann Med. 2019;51(3&#x2013;4):193&#x2013;223. doi: 10.1080/07853890.2019.1609076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2019.1609076</ArticleId><ArticleId IdType="pmc">PMC7877885</ArticleId><ArticleId IdType="pubmed">31007084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zar&#xe0; M, Guidetti GF, Camera M, Canobbio I, Amadio P, Torti M, et al. Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis. Int J Mol Sci. 2019;20(11):2840. doi: 10.3390/ijms20112840.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112840</ArticleId><ArticleId IdType="pmc">PMC6600675</ArticleId><ArticleId IdType="pubmed">31212641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly S, Basavaraj MG, Starikova I, Olsen R, Br&#xe6;kkan SK, Hansen J -B. Elevated plasma levels of P&#x2010;selectin glycoprotein ligand&#x2010;1&#x2010;positive microvesicles in patients with unprovoked venous thromboembolism. J Thromb Haemost. 2018;16(8):1546&#x2013;1554. doi: 10.1111/jth.14162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14162</ArticleId><ArticleId IdType="pubmed">29851269</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pol E, Sturk A, van Leeuwen T, Nieuwland R, Coumans F, Mobarrez F, et al. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. J Thromb Haemost. 2018;16(6):1236&#x2013;1245. doi: 10.1111/jth.14009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14009</ArticleId><ArticleId IdType="pubmed">29575716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J, Fu Y, Zhou J, Li W, Xie R, Cao F, et al. Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox Sang. 2011;100(2):187&#x2013;195. doi: 10.1111/j.1423-0410.2010.01375.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2010.01375.x</ArticleId><ArticleId IdType="pubmed">20738837</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Z, Liu F, Blair R, Wang C, Yang H, Mudd J, et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics. 2021;11(16):8076&#x2013;8091. doi: 10.7150/thno.61810.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.61810</ArticleId><ArticleId IdType="pmc">PMC8315069</ArticleId><ArticleId IdType="pubmed">34335981</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnhuber A, Flie&#xdf;er E, Gorkiewicz G, Zacharias M, Seeliger B, David S, et al. Between inflammation and thrombosis: endothelial cells in COVID-19. Eur Respir J. 2021;58(3):2100377. doi: 10.1183/13993003.00377-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00377-2021</ArticleId><ArticleId IdType="pmc">PMC8112008</ArticleId><ArticleId IdType="pubmed">33958433</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippe A, Chocron R, Bonnet G, Yatim N, Sutter W, Hadjadj J, et al. Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation. Arch Cardiovasc Dis. 2023 doi: 10.1016/j.acvd.2023.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9925415</ArticleId><ArticleId IdType="pubmed">36858909</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa M, Kanno H, Zhou Y, Xiao TH, Suzuki T, Ibayashi Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12(1):7135. doi: 10.1038/s41467-021-27378-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27378-2</ArticleId><ArticleId IdType="pmc">PMC8660840</ArticleId><ArticleId IdType="pubmed">34887400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell A, Havervall S, von Meijenfeldt F, Hisada Y, Aguilera K, Grover SP, et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality&#x2014;brief report. Arterioscler Thromb Vasc Biol. 2021;41(2):878&#x2013;882. doi: 10.1161/ATVBAHA.120.315547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315547</ArticleId><ArticleId IdType="pmc">PMC7837685</ArticleId><ArticleId IdType="pubmed">33267656</ArticleId></ArticleIdList></Reference><Reference><Citation>Campello E, Radu CM, Simion C, Spiezia L, Bulato C, Gavasso S, et al. Longitudinal trend of plasma concentrations of extracellular vesicles in patients hospitalized for COVID-19. Front Cell Dev Biol. 2022;9 doi: 10.3389/fcell.2021.770463.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.770463</ArticleId><ArticleId IdType="pmc">PMC8801799</ArticleId><ArticleId IdType="pubmed">35111751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamali HA, Saboor M, Dobie G, Madkhali AM, Akhter MS, Hakamy A, et al. Procoagulant Microvesicles in COVID-19 Patients: possible Modulators of Inflammation and Prothrombotic Tendency. Infect Drug Resist. 2022;15:2359&#x2013;2368. doi: 10.2147/IDR.S355395.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S355395</ArticleId><ArticleId IdType="pmc">PMC9064482</ArticleId><ArticleId IdType="pubmed">35517897</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, et al. Patient trajectories among persons hospitalized for COVID-19. Ann Intern Med. 2021;174(1):33&#x2013;41. doi: 10.7326/M20-3905.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3905</ArticleId><ArticleId IdType="pmc">PMC7530643</ArticleId><ArticleId IdType="pubmed">32960645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a Clinical Risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081. doi: 10.1001/jamainternmed.2020.2033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2033</ArticleId><ArticleId IdType="pmc">PMC7218676</ArticleId><ArticleId IdType="pubmed">32396163</ArticleId></ArticleIdList></Reference><Reference><Citation>Incerti D, Rizzo S, Li X, Lindsay L, Yau V, Keebler D, et al. Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA. BMJ Open. 2021;11(4) doi: 10.1136/bmjopen-2020-047121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-047121</ArticleId><ArticleId IdType="pmc">PMC8029269</ArticleId><ArticleId IdType="pubmed">33827848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, et al. Development and validation of the ISARIC 4C deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respir Med. 2021;9(4):349&#x2013;359. doi: 10.1016/S2213-2600(20)30559-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30559-2</ArticleId><ArticleId IdType="pmc">PMC7832571</ArticleId><ArticleId IdType="pubmed">33444539</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Cai GY, Fang W, Li HY, Wang SY, Chen L, et al. Machine learning based early warning system enables accurate mortality risk prediction for COVID-19. Nat Commun. 2020;11(1):5033. doi: 10.1038/s41467-020-18684-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18684-2</ArticleId><ArticleId IdType="pmc">PMC7538910</ArticleId><ArticleId IdType="pubmed">33024092</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;7. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13(1):1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, O&#x2019;Farrelly C, Tancevski I, L&#xf6;ffler-Ragg J, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28(5):879&#x2013;882. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Zhang H, Sun S, Wang L, Sun S. Extracellular vesicles and immunogenic stress in cancer. Cell Death Dis [Internet] 2021;12(10):894. doi: 10.1038/s41591-022-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pmc">PMC8486873</ArticleId><ArticleId IdType="pubmed">34599143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>